

S1 Table. Prior best response and progression-free survival (PFS) according to the first-line treatment regimens

Clinical efficacy	FP-based (n=17)	FP+Tmab (n=6)	FP+Pmab (n=4)	Total (n=27)	p-value
Best response					
PR	3 (17.6)	2 (33.3)	2 (50.0)	7 (25.9)	0.642
SD	12 (70.6)	3 (50.0)	2 (50.0)	17 (63.0)	
PD	2 (11.8)	1 (16.7)	0 (0.0)	3 (11.1)	
PFS (mo)					
Median (95% CI)	6.1 (4.1-8.2)	8.1 (2.7-13.6)	5.6 (1.1-10.1)	6.9 (2.8-11.1)	0.638

Values are presented as number (%). CI, confidence interval; FP, fluoropyrimidine and/or platinum; PD, disease progression; PFS, progression-free survival; Pmab, pembrolizumab; PR, partial response; SD, stable disease; Tmab, trastuzumab.